Literature DB >> 18422593

Investigation of early atherosclerotic changes in acromegalic patients.

I Kartal1, H Oflaz, B Pamukçu, M Meriç, F Aral, N Ozbey, F Alagöl.   

Abstract

BACKGROUND: Functional and morphological changes of endothelium were risk factors for mortality attributed to atherosclerosis. Studies investigating early atherosclerotic alterations and the effect of the treatment of acromegaly on these alterations gave conflicting results.
OBJECTIVE: Surrogate markers of early atherosclerotic changes, i.e. brachial artery flow-mediated dilation (FMD) and carotid artery intima-media-thickness (IMT) in active and inactive acromegalic patients were compared with control subjects matched to patients for age, sex and cardiovascular risk factors to find out the direct effects of growth hormone (GH)/insulin-like growth factor-1 excess.
METHODS: In 14 active acromegalics and their 14 matched controls, 14 inactive acromegalics and their 14 matched controls, carotid artery IMT and FMD of brachial artery were measured. Inactive acromegalics were in remission for at least 1 year.
RESULTS: Active acromegalics had higher IMT than matched controls and inactive acromegalics (0.85 +/- 0.20 mm, 0.64 +/- 1.77 mm, 0.66 +/- 0.20 mm respectively; p < 0.005, p < 0.05) and IMT of inactive acromegalics was not different from their matched controls (0.61 +/- 0.12 mm). FMD was significantly lower in active acromegalics than in matched controls and inactive acromegalics (2.910 +/- 2.00 mm, 6.5 +/- 2.81 mm, 5.68 +/- 2.9 mm respectively; p < 0.005, p < 0.05). FMD of inactive acromegalics was not significantly different from their matched controls (7.96 +/- 3.12 mm). A significant inverse relationship was found between GH and FMD in active acromegalics (r = -0.659, p = 0.010).
CONCLUSION: In active acromegalics, early atherosclerotic changes are not only attributed to the high prevalence of risk factors, but also to the abnormal GH secretion itself.

Entities:  

Mesh:

Year:  2008        PMID: 18422593     DOI: 10.1111/j.1742-1241.2008.01750.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  11 in total

Review 1.  Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.

Authors:  Ana M Ramos-Leví; Mónica Marazuela
Journal:  Endocrine       Date:  2017-01-02       Impact factor: 3.633

2.  Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly.

Authors:  H Ozkan; O Celik; E Hatipoglu; F Kantarci; P Kadioglu
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

3.  Circulating endothelial progenitor cells in acromegaly.

Authors:  G Bellastella; M I Maiorino; R Pivonello; L F S Grasso; M Galdiero; A A Sinisi; A Colao; D Giugliano; K Esposito
Journal:  J Endocrinol Invest       Date:  2013-06-26       Impact factor: 4.256

Review 4.  Improvement of cardiac parameters in patients with acromegaly treated with medical therapies.

Authors:  Annamaria Colao
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 5.  Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.

Authors:  Rosario Pivonello; Renata S Auriemma; Ludovica F S Grasso; Claudia Pivonello; Chiara Simeoli; Roberta Patalano; Mariano Galdiero; Annamaria Colao
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

6.  Low risk of coronary artery disease in patients with acromegaly.

Authors:  Cintia Marques Dos Santos Silva; G A B Lima; I C M Volschan; I Gottlieb; L Kasuki; L Vieira Neto; M R Gadelha
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

7.  Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.

Authors:  Cigdem Ozkan; Alev Eroglu Altinova; Ethem Turgay Cerit; Cagri Yayla; Asife Sahinarslan; Duygu Sahin; Aylin Sepici Dincel; Fusun Balos Toruner; Mujde Akturk; Metin Arslan
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

Review 8.  Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis.

Authors:  Matteo Parolin; Francesca Dassie; Chiara Martini; Roberto Mioni; Lucia Russo; Francesco Fallo; Marco Rossato; Roberto Vettor; Pietro Maffei; Claudio Pagano
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

9.  Low serm Fibroblast Growth Factor-21 levels is not associated with Carotid intima-media thickness in acromegaly patients.

Authors:  M M Uygur; D Dereli Yazıcı; D Gogas Yavuz
Journal:  J Endocrinol Invest       Date:  2022-03-25       Impact factor: 5.467

Review 10.  Chronic limb-threatening ischemia could benefit from growth hormone therapy for wound healing and limb salvage.

Authors:  Diego Caicedo; Pablo Devesa; Víctor M Arce; Julia Requena; Jesús Devesa
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.